Wells Fargo upgraded Merit Medical (MMSI) to Overweight from Equal Weight with a price target of $120, up from $103. The firm expects Wrapsody to be a significant catalyst to Merit Medical’s story in 2025 and sees consistent execution in other parts of the business. Merit has delivered 17 consecutive quarters of revenue beats, 14 quarters of operating margin growth, and steady gross margin improvement, the analyst tells investors in a research note. Wells says Wrapsody could deliver at least 70 basis points of additional growth through 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target raised to $127 from $125 at Canaccord
- Merit Medical’s WRAPSODY WAVE trial ‘exceeds performance goals’ for AVG patients
- Merit Medical completes acquisition of Cook Medical’s lead management portfolio
- Merit Medical price target raised to $109 from $107 at Baird
- Merit Medical Reports Strong Q3 2024 Earnings Growth